Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity

References

• Renu K, Abilash VG, Tirupathi Pichiah PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy – an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.04329074412
   PubMed Web of Science ®Google Scholar
• Damiani RM, Moura DJ, Viau CM, Caceres RA, Henriques JAP, Saffi J. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016;90(9):2063–2076. doi:10.1007/s00204-016-1759-y27342245
   PubMed Web of Science ®Google Scholar
• Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039–1058. doi:10.1517/14656566.8.8.103917516870
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–533. doi:10.1136/hrt.2007.13609318347383
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042–1049. doi:10.1200/JCO.2010.30.340422370326
   PubMed Web of Science ®Google Scholar
• Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA, Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26–30. doi:10.1016/j.lfs.2018.03.02329534993
   PubMed Web of Science ®Google Scholar
• Mitry MA, Edwards JG. Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc. 2016;10:17–24. doi:10.1016/j.ijcha.2015.11.00427213178
   PubMed Web of Science ®Google Scholar
• Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018;2018:1–15. doi:10.1155/2018/7582730
   Web of Science ®Google Scholar
• Broeyer FJF, Osanto S, Suzuki J, et al. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients. Br J Clin Pharmacol. 2014;78(5):950–960. doi:10.1111/bcp.1242924844787
   PubMed Web of Science ®Google Scholar
• Vincent DT, Ibrahim YF, Espey MG, Suzuki YJ. The role of antioxidants in the era of cardio-oncology. Cancer Chemother Pharmacol. 2013;72(6):1157–1168. doi:10.1007/s00280-013-2260-423959462
   PubMed Web of Science ®Google Scholar
• Zheng K, Li R, Zhou X, et al. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. Int J Nanomedicine. 2015;10:5327–5342. doi:10.2147/IJN.S8447826346331
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu Q, Wang N, et al. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth. Int J Nanomedicine. 2018;13:4549–4561. doi:10.2147/IJN.S17006730127606
   PubMed Web of Science ®Google Scholar
• Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007;2:567–583.18203425
   PubMed Web of Science ®Google Scholar
• Fang Y, Wang H, Dou H-J, et al. Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity. Int J Nanomedicine. 2018;13:5673–5683. doi:10.2147/IJN.S16120330288040
   PubMed Web of Science ®Google Scholar
• Yu J, Wang C, Kong Q, Wu X, Lu -J-J, Chen X. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine. 2018;40:125–139. doi:10.1016/j.phymed.2018.01.00929496165
   PubMed Web of Science ®Google Scholar
• Huang L, Zheng M, Zhou Y, et al. Tanshinone IIA attenuates cardiac dysfunction in endotoxin-induced septic mice via inhibition of NADPH oxidase 2-related signaling pathway. Int Immunopharmacol. 2015;28(1):444–449. doi:10.1016/j.intimp.2015.07.00426202805
   PubMed Web of Science ®Google Scholar
• Yu J, Gao H, Wu C, Xu Q-M, Lu -J-J, Chen X. Diethyl blechnic, a novel natural product isolated from salvia miltiorrhiza bunge, inhibits doxorubicin-induced apoptosis by inhibiting ROS and activating JNK1/2. IJMS. 2018;19(6):1809. doi:10.3390/ijms19061809
   Google Scholar
• Ogawa Y, Oku H, Iwaoka E, Iinuma M, Ishiguroa K. Allergy-preventive flavonoids from Xanthorrhoea hastilis. Chem Pharm Bull. 2007;55(4):675–678. doi:10.1248/cpb.55.67517409571
   PubMed Web of Science ®Google Scholar
• Kim YW, Zhao RJ, Park SJ, et al. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-κB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol. 2008;154(1):165–173. doi:10.1038/bjp.2008.7918332856
   PubMed Web of Science ®Google Scholar
• Jung EH, Lee J-H, Kim SC, Kim YW. AMPK activation by liquiritigenin inhibited oxidative hepatic injury and mitochondrial dysfunction induced by nutrition deprivation as mediated with induction of farnesoid X receptor. Eur J Nutr. 2017;56(2):635–647. doi:10.1007/s00394-015-1107-726646674
   PubMed Web of Science ®Google Scholar
• Kim YW, Ki SH, Lee JR, et al. Liquiritigenin, an aglycone of liquiritin in glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. Chem Biol Interact. 2006;161(2):125–138. doi:10.1016/j.cbi.2006.03.00816647697
   PubMed Web of Science ®Google Scholar
• Wätjen W, Weber N, Lou Y-J, et al. Prenylation enhances cytotoxicity of apigenin and liquiritigenin in rat H4IIE hepatoma and C6 glioma cells. Food Chem Toxicol. 2007;45(1):119–124. doi:10.1016/j.fct.2006.08.00817045382
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhou Y, Liu Y, Cai Y. Effect of liquiritigenin, a flavanone existed from radix glycyrrhizae on pro-apoptotic in SMMC-7721 cells. Food Chem Toxicol. 2009;47(4):693–701. doi:10.1016/j.fct.2008.12.01519150383
   PubMed Web of Science ®Google Scholar
• Liu C, Wang Y, Xie S, et al. Liquiritigenin induces mitochondria-mediated apoptosis via cytochrome c release and caspases activation in heLa Cells. Phytother Res. 2011;25(2):277–283. doi:10.1002/ptr.325920658471
   PubMed Web of Science ®Google Scholar
• Kim SC, Byun SH, Yang CH, Kim CY, Kim JW, Kim SG. Cytoprotective effects of glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). Toxicol. 2004;197(3):239–251. doi:10.1016/j.tox.2004.01.010
   PubMed Web of Science ®Google Scholar
• Xie X-W. Liquiritigenin attenuates cardiac injury induced by high fructose-feeding through fibrosis and inflammation suppression. Biomed Pharmacother. 2017;86:694–704. doi:10.1016/j.biopha.2016.12.06628039849
   PubMed Web of Science ®Google Scholar
• GU J, LI H, QIN K, et al. Determination of the equilibrium solubility and apparent oil/water partition coefficients of liquiritigenin using HPLC. Chin J Pharm Anal. 2013;33(8):1293–1297. doi:10.16155/j.0254-1793.2013.08.016
   Google Scholar
• Nasirideen S, Kaş HS, Öner F, Alpar R, Hıncal AA. Naproxen incorporated lipid emulsions. I. Formulation and stability studies. J Clin Pharm Ther. 1998;23(1):57–65. doi:10.1046/j.1365-2710.1998.00139.x9756113
   PubMed Web of Science ®Google Scholar
• Zhang T, Zheng Y, Peng Q, Cao X, Gong T, Zhang Z. A novel submicron emulsion system loaded with vincristine–oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. Int J Nanomedicine. 2013;8:1185–1196. doi:10.2147/IJN.S4177523658485
   PubMed Web of Science ®Google Scholar
• Li H, Pan T, Cui Y, et al. Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique. Int J Nanomedicine. 2016;11:3777–3788. doi:10.2147/IJN.S10541927540291
   PubMed Web of Science ®Google Scholar
• Rezaei A, Varshosaz J, Fesharaki M, Farhang A, Jafari SM. Improving the solubility and in vitro cytotoxicity (anticancer activity) of ferulic acid by loading it into cyclodextrin nanosponges. Int J Nanomedicine. 2019;14:4589–4599. doi:10.2147/IJN.S20635031296988
   PubMed Web of Science ®Google Scholar
• Hu X-B, Tang T-T, Li Y-J, et al. Phospholipid complex based nanoemulsion system for oral insulin delivery: preparation, in vitro, and in vivo evaluations. Int J Nanomedicine. 2019;14:3055–3067. doi:10.2147/IJN.S19810831118622
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Cai W, Sun P, Ding L, Jin F. Formulation, optimization, characterization, and pharmacokinetics of progesterone intravenous lipid emulsion for traumatic brain injury therapy. AAPS PharmSciTech. 2017;18(5):1475–1487. doi:10.1208/s12249-016-0637-527796907
   PubMed Web of Science ®Google Scholar
• Jumaa M, Müller BW. The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int J Pharm. 1998;163(1):81–89. doi:10.1016/S0378-5173(97)00369-4
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1):3–25. doi:10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Am J Hematol. 2004;76(4):319–329. doi:10.1002/ajh.2012015282663
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–1225. doi:10.1016/j.yjmcc.2012.03.00622465037
   PubMed Web of Science ®Google Scholar
• Granados-Principal S, El-azem N, Pamplona R, et al. Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem Pharmacol. 2014;90(1):25–33. doi:10.1016/j.bcp.2014.04.00124727461
   PubMed Web of Science ®Google Scholar
• Lin M, Yin M. Preventive effects of ellagic acid against doxorubicin-induced cardio-toxicity in mice. Cardiovasc Toxicol. 2013;13(3):185–193. doi:10.1007/s12012-013-9197-z23322372
   PubMed Web of Science ®Google Scholar
• Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol. 2011;50(3):408–416. doi:10.1016/j.yjmcc.2010.12.01821215757
   PubMed Web of Science ®Google Scholar
• Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med. 2002;33(7):988–997. doi:10.1016/S0891-5849(02)00989-912361808
   PubMed Web of Science ®Google Scholar
• Zhang Y-W, Shi J, Li Y-J, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp. 2009;57(6):435–445. doi:10.1007/s00005-009-0051-8
   PubMed Web of Science ®Google Scholar
• Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med. 2007;42(4):466–473. doi:10.1016/j.freeradbiomed.2006.11.01317275678
   PubMed Web of Science ®Google Scholar
• Khan M, Varadharaj S, Ganesan LP, et al. C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling. Am J Physiol Heart Circ Physiol. 2006;290(5):H2136–H2145. doi:10.1152/ajpheart.01072.200516373583
   PubMed Web of Science ®Google Scholar
• Lou H, Danelisen I, Singal PK. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;288(4):H1925–H1930. doi:10.1152/ajpheart.01054.200415772336
   PubMed Web of Science ®Google Scholar
• Li S, Mingyan E, Yu B. Adriamycin induces myocardium apoptosis through activation of nuclear factor κB in rat. Mol Biol Rep. 2008;35(4):489–494. doi:10.1007/s11033-007-9112-417577680
   PubMed Web of Science ®Google Scholar
• Wang Z-Q, Chen M-T, Zhang R, Zhang Y, Li W, Li Y-G. Docosahexaenoic acid attenuates doxorubicin-induced cytotoxicity and inflammation by suppressing NF-κB/iNOS/NO signaling pathway activation in H9C2 cardiac cells. J Cardiovasc Pharm. 2016;67(4):283. doi:10.1097/FJC.0000000000000350
   PubMed Web of Science ®Google Scholar
• Thomas CM, Yong QC, Rosa RM, et al. Cardiac-specific suppression of NF-κB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am J Physiol Heart Circ Physiol. 2014;307(7):H1036–H1045. doi:10.1152/ajpheart.00340.201425085967
   PubMed Web of Science ®Google Scholar
• El-Agamy DS, El-Harbi KM, Khoshhal S, et al. Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways. Cancer Manag Res. 2018;11:47–61. doi:10.2147/CMAR.S18669630588110
   PubMed Web of Science ®Google Scholar
• Gu J, Hu W, Song Z, Chen Y, Zhang D, Wang C. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. Int Immunopharmacol. 2016;32:1–7. doi:10.1016/j.intimp.2016.01.00226774212
   PubMed Web of Science ®Google Scholar
• Katamura M. Curcumin attenuates doxorubicin-induced cardiotoxicity by inducing autophagy via the regulation of JNK phosphorylation. J Clin Exp Cardiolog. 2014;05(09). doi:10.4172/2155-9880.1000337
   Google Scholar
• Smith CC, Guévremont D, Williams JM, Napper RM. Apoptotic cell death and temporal expression of apoptotic proteins Bcl-2 and Bax in the hippocampus, following binge ethanol in the neonatal rat model. Alcohol Clin Exp Res. 2015;39(1):36–44. doi:10.1111/acer.1260625623404
   PubMed Web of Science ®Google Scholar
• Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: bax ratio. Cancer Res. 2002;62(16):4592–4598.12183413
   PubMed Web of Science ®Google Scholar
• Li W, Lin X, Yang Z, et al. A bufadienolide-loaded submicron emulsion for oral administration: stability, antitumor efficacy and toxicity. Int J Pharm. 2015;479(1):52–62. doi:10.1016/j.ijpharm.2014.12.05425545797
   PubMedGoogle Scholar
• Weyenberg W, Filev P, Van den Plas D, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm. 2007;337(1):291–298. doi:10.1016/j.ijpharm.2006.12.04517300887
   PubMedGoogle Scholar